These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16983932)

  • 1. The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients.
    Suzuki H; Inoue T; Kobayashi K; Shoda J; Nakamoto H
    Adv Perit Dial; 2006; 22():18-23. PubMed ID: 16983932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.
    Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Fukuda T; Numao T; Shimada K; Kario K
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):394-400. PubMed ID: 17577104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azelnidipine and amlodipine: a comparison of their effects and safety in a randomized double-blinded clinical trial in Chinese essential hypertensive patients.
    Zhao X; Wu F; Jia S; Qu P; Li H; Zhao X; Cao B; Lin Y; Wang M
    Clin Exp Hypertens; 2010; 32(6):372-6. PubMed ID: 21029001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.
    Fujisawa M; Yorikane R; Chiba S; Koike H
    J Cardiovasc Pharmacol; 2009 Apr; 53(4):325-32. PubMed ID: 19295444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats.
    Shokoji T; Fujisawa Y; Kiyomoto H; Rahman M; Sun GP; Fan YY; Kimura S; Kohno M; Abe Y; Nishiyama A
    Hypertens Res; 2005 Dec; 28(12):1017-23. PubMed ID: 16671342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
    Nagasu H; Satoh M; Fujimoto S; Tomita N; Sasaki T; Kashihara N
    Hypertens Res; 2012 Mar; 35(3):348-55. PubMed ID: 22072106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
    Kimura Y; Hirooka Y; Sagara Y; Sunagawa K
    Clin Exp Hypertens; 2007 Jan; 29(1):13-21. PubMed ID: 17190727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine.
    Yamagishi T
    Hypertens Res; 2006 Oct; 29(10):767-73. PubMed ID: 17283863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension.
    Inomata J; Murai H; Kaneko S; Hamaoka T; Ikeda T; Kobayashi D; Usui S; Furusho H; Sugiyama Y; Takata S; Takamura M
    J Hypertens; 2014 Sep; 32(9):1898-904. PubMed ID: 24979307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity.
    Nada T; Nomura M; Koshiba K; Kawano T; Mikawa J; Ito S
    Arzneimittelforschung; 2007; 57(11):698-704. PubMed ID: 18193691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats.
    Nakamoto M; Ohya Y; Sakima A; Yamazato M; Takishita S
    Hypertens Res; 2007 Apr; 30(4):359-66. PubMed ID: 17541215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
    Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
    Hypertens Res; 2008 Dec; 31(12):2147-54. PubMed ID: 19139604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
    Konno S; Hirooka Y; Araki S; Koga Y; Kishi T; Sunagawa K
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):555-60. PubMed ID: 19057394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel actions of calcium channel blockers].
    Kumagai H; Onami T; Takimoto C; Iigaya K; Hayashi K
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():311-7. PubMed ID: 16983770
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT).
    Fukao K; Shimada K; Hiki M; Kiyanagi T; Hirose K; Kume A; Ohsaka H; Matsumori R; Kurata T; Miyazaki T; Daida H
    Cardiovasc Diabetol; 2011 Sep; 10():79. PubMed ID: 21906391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions.
    Yamada J; Tomiyama H; Matsumoto C; Yoshida M; Shiina K; Yamashina A
    J Cardiol; 2008 Apr; 51(2):114-20. PubMed ID: 18522784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
    Shinohara K; Hirooka Y; Ogawa K; Kishi T; Yasukawa K; Utsumi H; Sunagawa K
    Clin Exp Hypertens; 2012; 34(6):456-62. PubMed ID: 22471901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients.
    Koike Y; Kawabe T; Nishihara K; Iwane N; Hano T
    Hypertens Res; 2016 Dec; 39(12):863-867. PubMed ID: 27439493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial.
    Arita M; Hashizume T; Tanigawa K; Yamamoto H; Nishio I
    J Cardiovasc Pharmacol; 1999 Feb; 33(2):186-92. PubMed ID: 10028925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker].
    Sada T; Saito H
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):539-47. PubMed ID: 14639008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.